Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 17/20 | 0.60 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6341953 | 1.00 | SLC5A2 (0.60) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL6343834 | 0.90 | SLC5A2 (0.75) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL6345089 | 0.90 | SLC5A2 (0.75) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL6345844 | 0.90 | SLC5A2 (0.75) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL23992427 | 0.85 | SLC5A2 (0.81) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL6345651 | 0.84 | SLC5A1 (0.64) | SLC5A2SLC5A1 | |
| SCHEMBL6346645 | 0.84 | SLC5A1 (0.64) | SLC5A2SLC5A1 | |
| SCHEMBL6343629 | 0.82 | SLC5A2 (0.44) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL15215390 | 0.80 | SLC5A2 (0.61) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL15215343 | 0.80 | SLC5A2 (0.43) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2634184-B1 | C-ARYLGLUCOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS INC (CN) | 2015-10-14 | — | — | EP | disclosed |
| US-8871726-B2 | C-aryl glucoside derivative, preparation method therefor, and use thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2014-10-28 | — | — | US | disclosed |
| US-8871726-B2 | C-aryl glucoside derivative, preparation method therefor, and use thereof | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2014-10-28 | — | — | US | disclosed |
| EP-2634184-A1 | C-ARYLGLUCOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Allist Pharmaceuticals, Inc. (CN) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225514-A1 | C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20130225514-A1 | C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) | 2013-08-29 | — | — | US | disclosed |
| WO-2012055169-A1 | C-ARYLGLUCOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海艾力斯医药科技有限公司 (CN) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225514-A1 | C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ABCB11 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.